Biocon, India's largest biotherapeutics firm, is planning to hire around 1000 people in the coming months.
PLX-PAD, stem cell therapy for the treatment of critical limb ischemia (CLI) and end-stage of peripheral artery disease (PAD) by Pluristem Therapeutics, has been found safe in human trials.
Sanofi Aventis-owned Shantha Biotech is recalling five-in-one vaccines Shan5 from across global markets following safety concerns.
Lucentis (ranibizumab) may come as new treatment for vision loss due to diabetes, according to the findings from a new study.
India's Cadila Healthcare has reported a 67% jump in consolidated net profit has to Rs 505.14 crore from Rs 303.08 crore in the previous year during the year ended March 2010 on account of growth in formulation and APIs exports.
The sexually transmitted diseases gonorrhea could soon become a threat as most of the widely used antibiotics to treat the bacterial infection are increasingly getting ineffective due to resistance.
Cervical cancer vaccine Gardasil study, which has allegedly led to the death of 6 girls in Indian village of Khammam, was conducted in children before evaluating its safety in adult girls, senior officials with Indian government has stated.
Anti-blood clotting drug prasugrel (Effient) has been launched in India by Glenmark.
Anglo-Swedish pharmaceutical firm AstraZeneca has been made to pay a $510 million for illegally promoting its quetiapine (Seroquel) for diseases the anti-psychotic drug has not been approved in US.
Suven Life's investigative 5-HT compounds with a potential to treat neurodegenerative disorders won patents from New Zealand and India.